To include your compound in the COVID-19 Resource Center, submit it here.

Allogeneic expansion

How Adicet Bio is creating allogeneic therapies with its γδ T cell platform

Rather than taking the conventional approach of starting with autologous therapies, Adicet Bio Inc. is building an allogeneic pipeline from the get-go as part of the charge to make γδ T cells for solid and liquid cancers. The company thinks its ability to isolate and expand multiple subtypes of cell populations into disease-specific cell banks will allow

Read the full 572 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE